Evidence map›Paper›PMID 37231486›Full record

ArticleAddiction science & clinical practice2023

Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.

Mary L Geist, Andrea C Radick, Judith I Tsui, Kendra L Blalock, Addy Adwell, Elsabeth Tamru, Nancy C Connolly, Jocelyn R James

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction science & clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mary L GeistUniversity of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, USA.
Andrea C RadickDivision of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA.
Judith I TsuiDivision of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA.
Kendra L BlalockDivision of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA.
Addy AdwellHarborview Medical Center, 325 Ninth Avenue, P.O. Box 359780, Seattle, WA, 98104, USA.
Elsabeth TamruHarborview Medical Center, 325 Ninth Avenue, P.O. Box 359780, Seattle, WA, 98104, USA.
Nancy C ConnollyDivision of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA.
Jocelyn R JamesDivision of General Internal Medicine, Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, 325 Ninth Avenue, P. O. Box 359780, Seattle, WA, 98104, USA. jorose@uw.edu.ORCID 0000-0002-1980-6579
University of Washington · USHarborview Medical Center · US

Funding

The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western StatesR25DA050985 · NIDA · UNIVERSITY OF WASHINGTON · PI Judith Tsui · 2020 to 2026
$2.6M
NIDA NIH HHS R25 DA050985
6 · The paper itself

Abstract

backgroundThis study examined associations between receipt of hepatitis C (HCV) treatment and retention in office-based opioid treatment (OBOT) care.

methodsWe conducted a retrospective cohort study of HCV-infected patients who initiated OBOT treatment between December 2015 and March 2021 to characterize HCV treatment and assess associations with OBOT retention. HCV treatment was characterized as no treatment, early treatment (< 100 days since OBOT initiation) or late treatment (≥ 100 days). We evaluated associations between HCV treatment and cumulative days in OBOT. A secondary analysis using Cox Proportional Hazards regression was done to determine the rate of discharge over time when comparing those who did versus did not receive HCV treatment as a time-varying covariate. We also analyzed a subset of patients retained at least 100 days in OBOT care and evaluated whether HCV treatment during that period was associated with OBOT retention beyond 100 days.

resultsOf 191 HCV-infected OBOT patients, 30% initiated HCV treatment, of whom 31% received early treatment and 69% received late treatment. Median cumulative duration in OBOT was greater among those who received HCV treatment (any: 398 days, early: 284 days and late: 430 days) when compared to those who did not receive treatment (90 days). Compared to no HCV treatment, there were 83% (95% CI: 33-152%, P < 0.001), 95% (95% CI: 28%-197%, p = 0.002 and 77% (95% CI: 25-153%, p = 0.002) more cumulative days in OBOT for any, early and late HCV treatment, respectively. HCV treatment was associated with a lower relative hazard for discharge/drop-out, although results did not meet statistical significance (aHR = 0.59;95% CI: 0.34-1.00; p = 0.052). Among the subset of 84 patients retained in OBOT at least 100 days, 18 received HCV treatment during that period. Compared to those who did not receive treatment within the first 100 days, those who received treatment had 57% (95% CI: -3%-152%, p = 0.065) more subsequent days in OBOT.

conclusionsA minority of HCV-infected patients received HCV treatment after initiating OBOT treatment, but those who did had better retention. Further efforts are needed to facilitate rapid HCV treatment and evaluate whether early HCV treatment improves OBOT engagement.

Indexed as

BuprenorphineHepatitis COpioid-Related DisordersAnalgesics, OpioidHumansOpiate Substitution TreatmentRetrospective StudiesAnalgesics, OpioidBuprenorphineBuprenorphine retentionHepatitis c treatmentOffice-based buprenorphine treatment

Identifiers

PMID37231486
PMCPMC10210339
OpenAlexW4378176128

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.